Cargando…

Experiences in the design and implementation of phase II trials in CLL

Detalles Bibliográficos
Autores principales:	Cohen, Dena R, Hillmen, Peter, Brown, Julia M, Gregory, Walter M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287813/ http://dx.doi.org/10.1186/1745-6215-12-S1-A92

Ejemplares similares

Phase II trial designs for complex interventions: a single-arm single-stage design for clustered continuous outcomes
por: Wilson, Duncan T, et al.
Publicado: (2015)

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
por: Howard, Dena R., et al.
Publicado: (2016)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
por: Oughton, Jamie B., et al.
Publicado: (2017)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

A discussion of an issue relating to sample sizes of exact phase II trial designs
por: Howman, Andrew
Publicado: (2013)

Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design
por: Khan, Josephine, et al.
Publicado: (2013)

Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial
por: Hall, Peter, et al.
Publicado: (2015)

Adaptive designs for phase II cross-over dose-finding trials using Bayesian model averaging
por: Simpson, Sarah, et al.
Publicado: (2015)

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
por: Collett, Laura, et al.
Publicado: (2017)

Identifying appropriate phase II trial designs
por: Brown, Sarah R
Publicado: (2011)

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
por: Bühler, A, et al.
Publicado: (2016)

Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results
por: Bauche, Cécile, et al.
Publicado: (2014)

P649: SAFETY AND EFFECTIVENESS IN NAIVE CLL PATIENTS TREATED WITH VEN AND OBI UNDER REAL-WORLD CONDITIONS - COMPARISON OF PATIENTS IN LINE OR OUT OF SCOPE WITH CLL14 TRIAL.
por: Ingo, Schwaner, et al.
Publicado: (2023)

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses
por: Rawstron, Andrew C., et al.
Publicado: (2022)

P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
por: Sylvan, S Eketorp, et al.
Publicado: (2014)

A probability of benefit (AUC) approach to phase II cancer trials
por: Silcocks, Paul
Publicado: (2015)

SCNP identifies CLL donor subgroups by profiling functional immune signaling in the context of immune modulatory receptor expression
por: Le Scolan, Erwan, et al.
Publicado: (2015)

Use of electronic health records in the design and evaluation of implementation research in primary care - experiences from the aspire cluster randomised controlled trials (CRCTS)
por: Heudtlass, Peter, et al.
Publicado: (2015)

The importance of planning for a seamless transition in an adaptive phase II randomised trial
por: Marshall, Andrea, et al.
Publicado: (2011)

Modifying the multi-arm multi-stage (MAMS) design for use in a phase II tuberculosis trial in sub-Saharan Africa with a time-to-event primary outcome
por: Phillips, Patrick, et al.
Publicado: (2013)

Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019)

Enrolment and logistical challenges in TaMoVac 01 Phase I/II HIV trial despite the completion of an earlier (HIVIS-03 trial trial) in Dar es Salaam
por: Ngatoluwa, M, et al.
Publicado: (2012)

The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints
por: Jackson, Richard, et al.
Publicado: (2013)

Correcting for selection bias in two-stage trials with multiple correlated outcomes: application to seamless phase ii/iii clinical trials
por: Robertson, David, et al.
Publicado: (2015)

The STAR trial: can quality of life benefit offset any survival detriment?
por: Collinson, Fiona, et al.
Publicado: (2011)

Practical and methodological challenges in the design and implementation of a cluster-randomised feasibility trial of the management of urinary incontinence after stroke
por: Sutton, Chris J, et al.
Publicado: (2011)

P1596: PREDIAGNOSTIC ANTIMICROBIAL USE IN CLL, MM, FL AND DLBCL
por: Packness, E. M., et al.
Publicado: (2022)

Exploring non-compliance in a cluster randomised feasibility study to inform the design of the phase III trial
por: Bell, Lauren, et al.
Publicado: (2015)

The paediatric hepatic international tumour trial (PHITT): clinical trial design in rare disease
por: Moroz, Veronica, et al.
Publicado: (2015)

A phase II study of lenalidomide in patients with relapsed or refractory ATLL
por: Phillips, Adrienne A, et al.
Publicado: (2014)

Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014)

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2013)

Improving phase ii oncology trial using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien-Ju, et al.
Publicado: (2015)

A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)
por: Bensalem, A, et al.
Publicado: (2005)

Design and implementation of needs-specific critical care response teams
por: Hodder, R, et al.
Publicado: (2007)

P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL
por: Niemann, Carsten, et al.
Publicado: (2023)

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia
por: Howard, Dena R., et al.
Publicado: (2021)

Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure
por: Mebazaa, A, et al.
Publicado: (2004)

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
por: Jain, Nitin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mk0qnqbchrh8vg6dt4bm2off8i